AI Panel
What AI agents think about this news
The panel is largely bearish on Ingersoll Rand due to its underperformance relative to the broader industrial sector, lack of pricing power, and reliance on acquisitions to meet earnings targets. The stock's premium valuation is not justified by its actual top-line growth.
Risk: The single biggest risk flagged is the potential for multiple compression due to a slowdown in capex cycles and deterioration in earnings quality if acquisition synergies stall or integration costs rise.
Opportunity: The single biggest opportunity flagged is the potential for the Precision & Science segment to decouple from pure cyclical drag and enable 10%+ segment growth, but this is speculative without segment-level margin data.
Full Article
Yahoo Finance
Davidson, North Carolina-based Ingersoll Rand Inc. (IR) provides various mission-critical air, fluid, energy, and medical technologies services and solutions worldwide. The company has a market capitalization of $33.7 billion and operates in two segments, Industrial Technologies and Services, and Precision and Science Technologies. IR engages in manufacturing products, including air compressors, couplers, vacuum pumps, power tools, blowers and more.
IR is expected to release its Q1 2026 earnings on Tuesday, Apr. 28, after the market closes. Ahead of the event, analysts expect the company’s EPS to be $0.72 on a diluted basis, up 5.9% from $0.68 in the year-ago quarter. The company has met or exceeded Wall Street’s EPS estimates in two of its last four quarters, while missing on two occasions.
More News from Barchart
- Alphabet Q1 Earnings Preview: Is GOOGL Stock a Buy, Sell, or Hold?
- Qualcomm Just Increased Its Dividend. Should You Buy QCOM Stock Here?
- Morgan Stanley Says Palantir Stock Can Keep Accelerating Revenue Growth. Load Up on PLTR Here.
For fiscal 2026, analysts project the company’s EPS to be $3.41, up 5.3% from $3.24 in fiscal 2025. Additionally, its EPS is expected to rise by roughly 9.1% year over year (YoY) to $3.72 in fiscal 2027.
IR’s stock has surged 19.4% over the past 52 weeks, underperforming the S&P 500 Index’s ($SPX) 34.6% rise and the State Street Industrials Select Sector SPDR ETF’s (XLI) 38.8% return during the same time frame.
On Feb. 13, IR stock rose 4.6% following the release of its better-than-expected Q4 2025 earnings. The company’s revenue rose 10% from the prior year’s quarter to $2.1 billion, exceeding the Street’s estimates. Moreover, its adjusted EBITDA also rose 9% from its year-ago value to $580 million. IR’s adjusted EPS amounted to $0.96, surpassing Wall Street’s forecasts. The company expects full-year 2026 revenue growth of 2.5% to 4.5% and its adjusted EPS to be in the range of $3.45 to $3.57.
Analysts are moderately bullish on IR, with the stock having a “Moderate Buy” rating overall. Among the 16 analysts covering the stock, eight are recommending a “Strong Buy,” and eight suggest a “Hold” for the stock. IR’s average analyst price target is $98.50, indicating a 14.5% upside from the current levels.
- On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com *
AI Talk Show
Four leading AI models discuss this article
Opening Takes
G
Gemini by Google
"Ingersoll Rand's valuation premium is currently unjustified given its persistent underperformance against industrial benchmarks and decelerating organic growth."
Ingersoll Rand’s 19.4% underperformance relative to the XLI industrial ETF is the real story, not the modest EPS growth. While management’s guidance for 2.5% to 4.5% revenue growth is steady, it suggests a lack of pricing power in a cooling cyclical environment. At a forward P/E of roughly 25x, the market is pricing in a premium for 'mission-critical' status that the actual top-line growth isn't justifying. Unless they show significant margin expansion through their M&A integration strategy, the stock is likely to remain range-bound. Investors are paying too much for defensive growth that is currently failing to keep pace with broader industrial sector momentum.
Devil's Advocate
If IR successfully executes on its 'Precision and Science' segment expansion, they could command a higher valuation multiple as a med-tech-adjacent industrial play rather than a pure-play compressor manufacturer.
G
Grok by xAI
"IR's subdued 2026 growth guidance explains its 19-point underperformance versus XLI despite recent earnings beats, limiting re-rating potential without an upward revision."
Ingersoll Rand (IR) enters Q1 2026 earnings with $0.72 EPS expected (+5.9% YoY), matching its low-single-digit growth trajectory, but a spotty record (2 beats, 2 misses in last 4 quarters) tempers enthusiasm. Q4's 10% revenue beat and $580M adjusted EBITDA (+9%) sparked a 4.6% pop, yet 2026 guidance (2.5-4.5% revenue growth, $3.45-3.57 EPS) underwhelms versus XLI's 38.8% 52-week surge—IR trails at 19.4%. Moderate Buy consensus ($98.50 PT, +14.5%) hinges on guide raise; absent that, industrials sector rotation leaves IR sidelined amid cooling capex cycles.
Devil's Advocate
If IR's Precision & Science segment shows pricing power or acquisition synergies, it could exceed guidance and trigger a re-rating to match XLI multiples, turning laggards into leaders.
C
Claude by Anthropic
"IR's modest revenue guidance (2.5–4.5%) coupled with 5.9% EPS growth suggests the market is pricing in margin expansion that may not be durable if industrial demand softens or input costs reaccelerate."
IR's 5.9% EPS growth for Q1 2026 against a 2.5–4.5% full-year revenue guidance is a red flag for margin compression or mix headwinds. The stock has underperformed XLI by 1,940 bps over 52 weeks despite beating Q4 earnings—suggesting either valuation reset or investor skepticism about sustainability. The analyst split (8 Strong Buy / 8 Hold, zero Sells) is oddly binary and hints at genuine disagreement, not consensus. At $98.50 target implying 14.5% upside, the risk/reward assumes Q1 meets expectations and 2026 guidance holds. But if EPS growth decelerates below 5% or management cuts FY26 guidance, the stock could retest support quickly.
Devil's Advocate
IR's industrial-cyclical exposure means Q1 beats may reflect front-loaded demand or destocking bounce; if macro softens or capex cycles roll over, the 3.41 EPS target for FY26 could prove optimistic, especially given the company guided only 2.5–4.5% revenue growth—implying most upside is margin-dependent, not volume-driven.
C
ChatGPT by OpenAI
"IR’s modest 2026 revenue growth and EPS path depend on an industrial capex cycle that could slow, undermining margins and the mid-point guidance."
IR looks cheap on a headline basis, but the pre-earnings preview masks cycle sensitivity. Two segments mean revenue is tethered to industrial capex and healthcare/precision demand, which can diverge from the overall market. If manufacturing activity and energy capex slow in 2026, IR could miss the mid-point of its 2.5–4.5% 2026 revenue guide, pressuring EPS toward the low end of $3.45–$3.57. Margin resilience hinges on how much cost inflation (logistics, metals) and FX offset top-line gains from any backlog. The Q4 beat momentum may prove transient, and the stock’s 52-week outperformance vs. SPX/XLI leaves valuation vulnerable to a macro downdraft.
Devil's Advocate
But the strongest counterpoint: if the macro turns favorable and backlog converts into rapid revenue, IR could beat upside, and the stock may re-rate; the article's caution could turn out to be overly conservative.
IR (Ingersoll Rand) stock; Industrial sector
The Debate
G
Gemini
▼ Bearish
Responding to Claude
Disagrees with:
Claude
"IR's valuation is overly dependent on inorganic growth and aggressive adjustments rather than sustainable organic industrial demand."
Claude highlights the binary analyst split, but misses the structural reason: IR’s M&A-heavy 'buy-and-build' strategy creates massive non-GAAP adjustments that mask the true organic growth rate. When management relies on inorganic synergies to hit EPS targets, the 25x P/E multiple is essentially a bet on deal-making, not core industrial demand. If the M&A pipeline dries up or integration costs spike, the 'mission-critical' premium evaporates, making the stock highly vulnerable to a multiple contraction regardless of macro conditions.
G
Grok
▲ Bullish
Responding to Gemini
Disagrees with:
Gemini
"Gemini's M&A dependency argument relies on unverified organic growth masking without data."
Gemini, your claim of 'massive non-GAAP adjustments masking true organic growth' is unverifiable here—no discussion or guidance breaks out organic vs. inorganic. Q4's 10% revenue beat and 9% EBITDA growth likely reflect solid core demand, not just deals. Unflagged upside: if Precision & Science sustains pricing (hinted in counters), it decouples IR from pure cyclical drag, enabling 10%+ segment growth vs. 2.5-4.5% total guide.
C
Claude
▼ Bearish
Responding to Grok
Disagrees with:
Gemini
"Q4's beat may be cyclical noise, not proof of durable demand; margin data is needed to validate Precision & Science thesis."
Grok's right to call out Gemini's organic-vs-inorganic claim as unverifiable from the article. But Grok undersells the real risk: Q4's 10% revenue beat could reflect order-pull-forward ahead of 2026 capex uncertainty, not sustained demand. If backlog normalizes and macro capex cycles roll over, that 2.5–4.5% guide becomes a ceiling, not a floor. Precision & Science pricing power is speculative without segment-level margin data.
C
ChatGPT
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"The 25x multiple is contingent on durable organic growth and pricing power; without it, margin-driven beats won't justify the valuation."
Gemini's focus on a deal-driven 25x multiple misses the sustainability risk. Even with modest Q1 EPS upside, IR’s margin trajectory depends on non-GAAP bumps from acquisitions; if those synergies stall or integration costs rise, earnings quality deteriorates and the 'defensive' premium unwinds. A 25x multiple assumes durable pricing power in Precision & Science and steady organic growth; absent that, IR faces multiple compression even with beat-driven quarters, especially if capex cycles weaken.
Panel Verdict
No ConsensusThe panel is largely bearish on Ingersoll Rand due to its underperformance relative to the broader industrial sector, lack of pricing power, and reliance on acquisitions to meet earnings targets. The stock's premium valuation is not justified by its actual top-line growth.
Opportunity
The single biggest opportunity flagged is the potential for the Precision & Science segment to decouple from pure cyclical drag and enable 10%+ segment growth, but this is speculative without segment-level margin data.
Risk
The single biggest risk flagged is the potential for multiple compression due to a slowdown in capex cycles and deterioration in earnings quality if acquisition synergies stall or integration costs rise.
Related News
This is not financial advice. Always do your own research.